期刊文献+

炎性因子在阿尔茨海默病发病机制中的作用 被引量:7

Role of inflammatory cytokines in pathogenesis of Alzheimer’ s disease
下载PDF
导出
摘要 阿尔茨海默病( AD)是老年人中最常见的、但病因尚未明确的渐进性神经系统退行性疾病,其主要临床表现为进行性认知功能障碍、学习记忆能力减退、日常行为异常、生活能力下降以及人格改变等症状。神经元外淀粉样β蛋白(Aβ)沉积、神经元内神经原纤维缠结( NFT)、神经突触及神经元丢失等为其主要病理学特征性变化,这些变化诱发了神经炎症反应。AD发病机制及病因复杂多样,目前主要有Aβ级联假说、tau蛋白异常磷酸化、神经炎症反应等,越来越多的研究表明炎症反应在AD发病进程中扮演重要角色。本文将对部分炎性因子[IL-1β、IL-6、IL-4、IL-10、转化生长因子β1(TGF-β1)和肿瘤坏死因子α( TNF-α)等]与AD的关系做一综述。 Alzheimer’s disease (AD) has been regarded as one of the most common neurodegenerative diseases, and is mainly manifested as progressive cognitive dysfunction, memory and learning decline, abnormal daily behavior, personality changes and decline in activities of daily living though its cause remains unclear.The main pathological features of AD have been revealed as deposition of amyloidβ-protein( Aβ) , neurofibrillary tangles ( NFTs) , synaptic and neuronal loss etc., and these changes contribute to neurological inflammatory responses.The etiology and pathogenesis of AD are quite complex and diverse, and current most prevailing hypotheses include Aβcascade hypothesis, abnormal phosphorylation of tau protein, nerve inflammation and so on.Much evidence showed that the inflammation response played important roles in the development and progression of AD.In this paper, we reviewed the relationship of some inflammatory cytokines[IL-1β, IL-6, IL-4, IL-10, transforming growth factor-β1 (TGF-β1), tumor necrosis factor-α( TNF-α) and others] with AD.
出处 《中华老年多器官疾病杂志》 2016年第9期713-716,共4页 Chinese Journal of Multiple Organ Diseases in the Elderly
基金 2014年度上海市卫生和计划生育委员会科研课题重点项目(201440022)~~
关键词 炎性因子 阿尔茨海默病 发病机制 inflammatory factors Alzheimer’ s disease pathogenesis
  • 相关文献

参考文献23

  • 1Nuzzo D, Picone P, Caruana L, et al. Inflammatol"y mediators as biomarkers in brain disorders [ J ]. Inflammation, 2014, 37 (3) : 639 - 648.
  • 2Wang J, Tan L, Wang HF, et al. Anti-inflammatory drugs and risk of Alzheimer' s disease: an updated systematic review and meta-analysis[ J]. J Alzheimers Dis, 2015, 44(2) : 385 - 396.
  • 3Heneka MT, Carson MJ, E1 Khoury J, et al. Neuroinflammation in Alzheimer' s disease [ J ]. Lancet Neurol, 2015, 14 (4) : 388 - 405.
  • 4Kummer MP, Heneka MT. Truncated and modified amyloid-beta species[J]. Alzheimers Res Ther, 2014, 6(3): 28.
  • 5Lloret A, Fuchsberger T, Giraldo E, et al. Molecular mechanisms linking amyloid 13 toxicity and Tau hyperphosphorylation in Alzheimer' s disease [ J ]. Free Radic Biol Med, 2015, 83 : 186 - 191.
  • 6Karcb CM, Goate AM. Alzheimer' s disease risk genes and mechanisms of disease pathogenesis [ J]. Biol Psychiatry, 2015, 77(1):43-51.
  • 7Villegas-Llerena C, Phillips A, Gareia-Reitboeck P, et al. Mieroglial genes regulating neuroinflammation in the progression of Alzheimer' s disease [ J ]. Curr Opin Neurobiol, 2016, 36: 74 - 81.
  • 8Sil S, Ghosh T, Ghosh R. NMDA receptor is involved in neuro- inflammation in intracerebroventrieular colehieine-injeeted rats[J]. J Immunotoxicol, 2016, 20:1 -16.
  • 9Couturier J, Stancu IC, Schaknmn O, et al. Activation of phagocytic activity in astrocytes by reduced expression of the inflammasomecomponent ASC and its implication in a mouse model of Alzheimer' s disease [ J]. J Neuroinflammation, 2016, 13 : 20.
  • 10Kummer MP, Hammerschmidt T, Martinez A, et al. Ear2 deletion causes early memory and learning deficits in APP/PSI mice[ J]. J Neurosci, 2014, 34(26): 8845-8854.

二级参考文献16

  • 1Pomponi M, Di Gioia A, Bria P, et al. Fatty aspirin: a new perspective in the prevention of dementia of Alzheimer's type[J]? Curr Alzheimer Res, 2008, 5(5): 422-431.
  • 2Sabbagh MN. Drug development for Alzheimer's disease: where are we now and where are we headed[J]? Am J Geriatr Pharmacother, 2009, 7(3): 167-185.
  • 3In't Veld BA, Launer L J, Breteler MM, et al. Pharmacologic agents associated with a preventive effect on Alzheimer's disease: a review of the epidemiologic evidence[J]. Epidemiol Rev, 2002, 24(2): 248-268.
  • 4Nilsson SE, Johansson B, Takkinen S, et al. Does aspirin protect against Alzheimer's dementia? A study in a Swedish population-based sample aged I> 80 years[J]. Eur J Clin Pharmacol, 2003, 59(4): 313-319.
  • 5Landi F, Cesari M, Onder G: et al. Non-steroidal anti-inflammatory drug (NSAID) use and Alzheimer disease in community-dwelling elderly patients[J]. Am J Geriatr Psychiatry, 2003, 11(2): 179-185.
  • 6Auriel E, Regev K, Korczyn AD. Nonsteroidal anti-inflammatory drugs exposure and the central nervoussystem[J]. Handb Clin Neurol, 2014, 119:577-584.
  • 7Hirohata M, Ono K, Naiki H, et al. Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's [3-amyloid fibrils in vitro[J]. Neuropharmacology, 2005, 49(7): 1088-1099.
  • 8Tortosa E, Avila J, Perez M. Acetylsalicylic acid decreases tau phosphorylation at serine 422[J]. Neurosci Lett, 2006, 396(1): 77-80.
  • 9Iwata R, Kitagawa K, Zhang NY, et al. Non-steroidal anti-inflammatory drugs protect amyloid 13 protein-induced increase in the intracellular C1- concentration in cultured rat hippocampal neurons[J]. Neurosci Lett, 2004, 367(2): 156-159.
  • 10Asanuma M, Nishibayashi-Asanuma S, Miyazaki I, et al. Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals[J]. J Neurochem, 2001, 76(6): 1895-1904.

共引文献3

同被引文献77

引证文献7

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部